MIFH
TCRT icon

Migdal Insurance & Financial Holdings’s Alaunos Therapeutics TCRT Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,644
Closed -$888K – 671
2021
Q1 		$888K Buy
1,644
+1,020
+163% +$635K 0.01% 256
2020
Q4 		$236K Buy
+624
New +$248K ﹤0.01% 300

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Migdal Insurance & Financial Holdings's TCRT Position: Q2 2021 in Review

Migdal Insurance & Financial Holdings sold out of Alaunos Therapeutics (TCRT) in Q2 2021, closing a stake of 1,644 shares — an estimated $888K sold.

Migdal Insurance & Financial Holdings first reported a position in TCRT in Q4 2020 and held it in 2 quarters. The position peaked at $888K in Q1 2021. 155 funds tracked by Wall St. Rank hold TCRT as of Q2 2021.

  • Migdal Insurance & Financial Holdings reported no remaining Alaunos Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 1,644 Alaunos Therapeutics shares in Q2 2021, an estimated $888K.
  • Migdal Insurance & Financial Holdings first reported a position in Alaunos Therapeutics in Q4 2020 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Alaunos Therapeutics position peaked at $888K in Q1 2021.
  • 155 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2021.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q2 2021, filed 4 Aug 2021.